Other upcoming conferences produced by EOCI include:

Congress Learning Objectives

Following this program, participants will be able to:

  • Approach and better manage the increasing problem of cardiotoxicity as it relates to heart failure
  • Identify how recent advances in genetics will impact the referral and treatment of heart failure patients
  • Describe the novel biomarker journey from bench to clinical care of heart failure
  • Describe the unique interactions between diabetes and heart failure
  • Discuss new and emerging concepts in heart failure with preserved ejection fraction

Joint Plenary Session: Precision Medicine: Patient, Population, or Both?

Can macrodata predict response to therapy?

Larry Allen, MD

Following this session, participants will be better able to:

  1. Criticize how well we can deliver precision medicine based on population-based health data
  2. Assess the importance of selecting high- and low-risk groups to target - as well as the factors that identify levels of risk
  3. Identify strategies to reduce health care utilization and improve outcomes at the individual patient level

Genes to genomes: evolution of molecular testing for inherited cardiomyopathy

Birgit Funke, PhD

Following this session, participants will be better able to:

  1. Describe inherited cardiomyopathies
  2. Predict, through lessons learned over a decade, when to consider or refer patients for clinical genetic testing
  3. Assess which genes should be tested for clinical validity as well as standards for assessing validity of gene-disease/variant-disease relationships

The journey of the biomarker from bench to bedside

Douglas Lee, MD

Following this session, participants will be better able to:

  1. Discuss how novel biomarkers are identified and validated
  2. Analyze how biomarkers are applied to clinical care of patients with heart failure
  3. Forecast the coming biomarker candidates trends in cardiovascular medicine

Joint Plenary Session: Evolving Concepts in Heart Failure

Amlodipine therapy for iron-overload cardiomyopathy: The enduring value of translational research.

Gavin Oudit, MD

Following this session, participants will be better able to:

  1. Describe the pathophysiology of iron-overload cardiomyopathy
  2. Discuss the suitability of amlodipine as a therapy for this condition
  3. Review existing and novel screening and diagnostic methods for iron overload

Heart failure with and without atrial fibrillation: Are they different diseases?

Martin Cowie, MD

Following this session, participants will be better able to:

  1. Describe the epidemiology of heart failure with, and without, atrial fibrillation
  2. Describe how atrial fibrillation impacts the prognosis and treatment of patients with heart failure
  3. Critique whether treatment of atrial fibrillation can prevent heart failure or improve the management of those who have it

Update on ischemic conditioning: Bench to bedside opportunities for clinical translation

Nicolas Noiseux, MD

Following this session, participants will be better able to:

  1. Discuss ischemia-reperfusion injury
  2. Describe the concept of ischemic conditioning for cardioprotection and interpret the latest clinical evidence
  3. Define future strategies for efficient cardioproptection and development of post-conditioning agents

Joint Plenary Session: Sweet Failure: HFpEF and Diabetes

Targeting the diagnosis of HFpEF

Justin Ezekowitz, MB BCh

Following this session, participants will be better able to:

  1. Review clinical, imaging and biochemical markers of HFpEF and whether they can provide therapeutic guidance
  2. Discuss how the diagnosis of HFpEF can be refined
  3. Discuss how we can subdivide the HFpEF population

New and emerging Heart Failure therapies: 2018 and Beyond

John McMurray, MD

Following this session, participants will be better able to:

  1. Describe novel investigative treatments for HFpEF
  2. Assess surprising clinical trial results irrespective of left ventricle ejection fraction
  3. Evaluate the landscape of therapies for heart failure and mid-range ejection fraction

Diabetic cardiomyopathy: real or imagined?

Kim Connelly, MBBS, PhD

Following this session, participants will be better able to:

  1. Discuss the interrelationships between glucose metabolism and myocardial function
  2. Describe energy deficiencies in the heart
  3. Assess the pathogenesis and presentation of diabetic cardiomyopathy

Joint Plenary Session: What we must know about cardiotoxicity

Why cardiologists must care about cancer immunotherapy

Javid Moslehi, MD

Following this session, participants will be better able to:

  1. Describe immunotherapy
  2. Translate how the effects of immunotherapy can lead to the development of heart failure
  3. Review the preventative steps that can protect the hearts of cancer patients

Clonal hematopoiesis: A pathway to cancer, a pathway to heart disease

Aaron Schimmer, MD

Following this session, participants will be better able to:

  1. Define clonal hematopoiesis
  2. Describe the significance of clonal hematopoiesis in cancer
  3. Analyze how clonal hematopoiesis is relevant to the development of cardiovascular disease

Novel diagnosis and treatment of cardiac amyloidosis: can we cure the incurable?

Natalie Galant, PhD

Following this session, participants will be better able to:

  1. Define the pathophysiology and epidemiology of cardiac amyloidosis
  2. Identify the varieties of amyloidosis and summarize their significance
  3. Estimate how to diagnose and potentially treat transthyretin amyloidosis

Ted Rogers Centre Scientific Sessions

How to Engineer a Heart

Biomaterials that improve heart function

Ren-Ke Li, MD

Following this session, participants will be better able to:

  1. Express why cardiac conduction is an important factor in heart failure
  2. Summarize how we can improve cardiac conduction in scarred hearts
  3. Describe new research using conductive biomaterials to improve cardiac fibrotic tissue conductive velocity

The genomic blueprint of the heart

Benoit Bruneau, MD

Following this session, participants will be better able to:

  1. Discuss novel genomic concepts in heart development
  2. Assess how such concepts can be applied to modeling human disease in engineered iPS cells

Importance of vasculature to heart regeneration

Sara Vasconcelos, PhD

Following this session, participants will be better able to:

  1. Define how tissue-engineered hearts derive nutrients
  2. Describe how vasculature improves tissue-engineered heart muscle

Cardiac Signalling & Metabolism

Can modulating cardiac metabolism prevent heart failure?

Mansoor Husain, MD

Following this session, participants will be better able to:

  1. Describe how disturbed metabolism can result in heart failure
  2. Review available therapies that modulate cardiac metabolism
  3. Discuss whether such therapies can be used to treat heart failure

HDL and cell signaling in the heart: Roles in cardioprotection

Bernardo Trigatti, PhD

Following this session, participants will be better able to:

  1. To review the role of HDL and the HDL receptor SR-B1 in regulating reverse cholesterol transport
  2. To understand the role of HDL and SR-B1 in protection against atherosclerosis
  3. To discuss emerging evidence that HDL and SR-B1 mediate direct cardioprotection

Apelin Analogues as Novel Therapies for Cardiovascular Disease

Gavin Oudit, MD

Following this session, participants will be better able to:

  1. Describe the cardioprotective effects of apelin analogues
  2. Discuss how apelin analogues regulate various cell signaling processes
  3. Describe the role of the apelin pathway in heart failure

The Importance of Genomics to our Understanding of Heart Disease

Genomic-guided therapies: Can we cure cardiomyopathy?

Carolyn Ho, MD

Following this session, participants will be better able to:

  1. Describe the underlying purpose of genomic medicine
  2. Relate how genomic information can be used to guide the treatment of cardiomyopathy

How deep learning can predict cardiac arrest

Anna Goldenberg, PhD

Following this session, participants will be better able to:

  1. Describe the potential of machine learning in application to streaming health data
  2. Detail how these tools can help the management of cardiac patients

A novel biomarker for arrhythmogenic cardiomyopathy

Robert Hamilton, MD

Following this session, participants will be better able to:

  1. Describe the epidemiology and pathophysiology of the ARVC biomarker
  2. Summarize how novel biomarkers are identified
  3. Assess the utility of biomarkers in diagnosing and treatment cardiomyopathy

CHFS Clinical Workshops

CCS Comprehensive Heart Failure Guidelines

Michael McDonald, MD
Eileen O'Meara, MD

After this workshop, participants will be able to:

  1. Describe a clear approach to the diagnosis of HF and determination of HF etiology (through case-based discussions)
  2. Optimize HF therapy considering the patient's profile and new data on individualized medicine, evaluating which drugs or device works best for which patients
  3. Identify patients with poor prognosis and develop an approach to end of life discussions

Ms. Understood: Gender-based differences and heart failure therapies: Drugs, Devices and Surgery

Shelley Zieroth, MD
Vivek Rao, MD

After this workshop, participants will be able to:

  1. Discuss what differences are involved in how women and men respond to treatments for heart failure
  2. Describe how men and women may respond differently after surgical interventions, based on evidence
  3. Employ gender-specific strategies for medication, devices and surgical procedures for heart failure

What patient advocacy means in 2018

Jillianne Code, PhD
Sean Virani, MD

After this workshop, participants will be able to:

  1. Identify how to build, nurture and leverage patient networks
  2. Interpret what patients want clinicians to do on their behalf
  3. Recognize key methods to empower the patient voice

Bridging the gap between clinical science medicine and basic science: Opening Pandora’s box

Phyllis Billia, MD
Anthony Gramolini, PhD

After this workshop, participants will be able to:

  1. Discuss challenges, potential solutions and examples for integrating basic science programs with clinical care
  2. Describe translational research programs and how they can be integrated into clinical care
  3. Discuss biobanking in large clinical centres and how they can provide important clinical information

Nursing: Managing Goals of Care

Pat Strachan, RN, PhD
Leah Steinberg, MD

After this workshop, participants will be able to:

  1. Recognize opportunities to engage in GOC discussions with patients with advanced HF and their families
  2. Learn an approach to GOC discussions with patients with advanced HF and their families including specific communication strategies and skills to improve these discussions
  3. Using video material, engage in skill development in GOC discussions

Cardiorenal Disease

Nadia Giannetti, MD

Following this session, participants will be better able to:

  1. Describe the different types of cardiorenal syndromes
  2. Asses how to best approach cardiorenal syndrome from the cardiology perspective
  3. Employ strategies to mitigate renal effects of heart failure treatments

Nursing: Initiation & titration of HF medications

Karen Harkness, RN, PhD
Serge Lepage, MD

After this workshop, participants will be able to:

  1. Interpret the evidence-based pharmacological management of chronic heart failure
  2. Discuss strategies for promoting patient adherence to medications
  3. Employ practical tips for creating a patient-centered approach to medication optimization

Advanced HF therapies: When to refer patients

Stephanie Poon, MD

After this workshop, participants will be able to:

  1. Recognize the signs and symptoms of early-onset cardiogenic shock
  2. Discuss the comorbidities that may limit the usefulness of advanced heart failure therapies
  3. Describe how to manage and evaluate heart failure patients in cardiogenic shock awaiting transfer for advanced heart failure therapies

Imaging Tools for HF in 2018

Nowell Fine, MD
Carolina Alba, MD

After this workshop, participants will be able to:

  1. Discuss imaging techniques for the evaluation and diagnosis of the heart failure patient
  2. Describe how imaging is used for the management guidance and surveillance of the heart failure patient